H.C. Wainwright lowered the firm’s price target on Kala Pharmaceuticals (KALA) to $12 from $15 and keeps a Buy rating on the shares following the Q3 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA:
- Kala Pharmaceuticals Advances KPI-012 in Clinical Trials
- Kala Pharmaceuticals reports Q1 EPS ($1.41) vs ($4.20) last year
- Kala Pharmaceuticals Announces Executive Retention Agreements
- Kala Pharmaceuticals: Promising Clinical Developments and Financial Stability Support Buy Rating
- Kala Pharmaceuticals management to meet with Oppenheimer